EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation

Qing Zhou, Jie Li, Shun-Dong Cang, Jia-Xin Lin, Hai-Yan Tu, Yingying Du, Jian-Wen Qin, Xiao-Hua Liang, Yan Yu, Hai-Tao Lan, Hua-Qiu Shi, Dong Hua und 2 weitere

Clinical Lung Cancer · 2025

DOI: 10.1016/j.cllc.2024.09.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2025. Verfasst von Qing Zhou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzh…. Hauptthemen laut MEDLINE: Acrylamides, Aniline Compounds, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Osimertinib, the 3rd generation EGFR-TKI, has emerged as standard first-line treatment for patients with advanced EGFR mutated nonsmall cell lung cancer (NSCLC). Patients with exon 21 L858R mutation showed lower efficacy with EGFR-TKIs than those with 19Del mutation, even with osimertinib, it remains an unmet medical need to further improve the efficacy in L858R population. We present the rationale and design for FLAIR (NCT04988607), which will investigate the efficacy and safety of osimertinib plus bevacizumab versus osimertinib monotherapy in treatment-naïve recurrent or metastatic NSCLC patients harboring EGFR exon 21 L858R mutation. MATERIALS AND METHODS: FLAIR is a prospective, multicenter, randomized, open label study, which is initiated by Chinese Thoracic Oncology Group (CTONG2002). Patients age ≥18 years with primary recurrent or metastatic nonsquamous NSCLC who are treatment-naïve with documented EGFR exon 21 L858R mutation is eligible. Patients will be randomized 1:1 to receive osimertinib 80 mg once daily plus bevacizumab 15mg/kg every 3 weeks or osimertinib monotherapy 80 mg once daily until progression or another discontinuation criterion is met. The primary endpoint is investigator-assessed progression free survival (PFS). Secondary endpoints include: overall survival rate at 24 months, time to treatment failure (TTF), overall response rate (ORR), disease control rate (DCR), duration of response (DoR), central nervous system (CNS) PFS, CNS ORR and safety. RESULTS: FLAIR has completed the enrollment, and results are expected in the fourth quarter of 2025 (depending on the actual event rate). CONCLUSIONS: This study will offer better perspectives on the efficacy and safety of osimertinib plus bevacizumab combination therapy in treatment-naïve recurrent or metastatic NSCLC patients harboring EGFR exon 21 L858R mutation, providing valuable guidance for clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesAniline CompoundsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasm Recurrence, LocalAdultAgedFemaleHumansMaleMiddle AgedClinical Trials, Phase II as TopicErbB ReceptorsMutationProspective StudiesRandomized Controlled Trials as TopicMulticenter Studies as TopicIndolesPyrimidines

Stichwörter der Autor:innen

EGFR L858R mutationEGFR-TKIFirst-line treatmentNon-small cell lung cancerOsimertinib plus bevacizumab

Substanzen

AcrylamidesAniline CompoundsBevacizumabEGFR protein, humanErbB ReceptorsosimertinibIndolesPyrimidines

Autor:innen und Institutionen

  • Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
  • Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
  • Department of Medical Oncology, Henan Provincial People's Hospital, Zhengzhou, China.
  • Pulmonary Medicine, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, China.
  • Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Respiratory Medicine, Tianjin Chest Hospital, Tianjin, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhou, Q., Li, J., Cang, S. D., Lin, J. X., Tu, H. Y., Du, Y., Qin, J. W., Liang, X. H., Yu, Y., Lan, H. T., Shi, H. Q., Hua, D., Liu, S. M., & Wu, Y. L. (2025). FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.09.002

Vancouver

Zhou Q, Li J, Cang SD, Lin JX, Tu HY, Du Y, et al. FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation. Clinical Lung Cancer. 2025. doi:10.1016/j.cllc.2024.09.002

BibTeX
@article{Zhou2025,
  author = {Zhou, Qing and Li, Jie and Cang, Shun-Dong and Lin, Jia-Xin and Tu, Hai-Yan and Du, Yingying and Qin, Jian-Wen and Liang, Xiao-Hua and Yu, Yan and Lan, Hai-Tao and Shi, Hua-Qiu and Hua, Dong and Liu, Si-Yang Maggie and Wu, Yi-Long},
  title = {FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation},
  journal = {Clinical Lung Cancer},
  year = {2025},
  doi = {10.1016/j.cllc.2024.09.002}
}
Kostenlos starten →